期刊
ALZHEIMERS & DEMENTIA
卷 15, 期 6, 页码 776-787出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2019.03.007
关键词
Alzheimer's disease; Biomarker; Plasma; Inflammation; Complement
资金
- Wellcome Trust [104025/Z/14/Z]
- National Institute for Health Research under its Biomedical Research Centers initiative
- MRC [UKDRI-3002, G108/603, MC_PC_17215, MR/P024572/1] Funding Source: UKRI
Introduction: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a Holy Grail of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOe4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation. (C) 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据